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Pertussis Toxin, an Inhibitor of Gai PCR, Inhibits Bile Acid-
and Cytokine-Induced Apoptosis in Primary Rat
Hepatocytes
Golnar Karimian*, Manon Buist-Homan, Klaas Nico Faber, Han Moshage
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Abstract
Excessive hepatocyte apoptosis is a common event in acute and chronic liver diseases leading to loss of functional liver
tissue. Approaches to prevent apoptosis have therefore high potential for the treatment of liver disease. G-protein coupled
receptors (GPCR) play crucial roles in cell fate (proliferation, cell death) and act through heterotrimeric G-proteins. GaiPCRs
have been shown to regulate lipoapoptosis in hepatocytes, but their role in inflammation- or bile acid-induced apoptosis is
unknown. Here, we analyzed the effect of inhibiting GaiPCR function, using pertussis toxin (PT), on bile acid- and cytokine-
induced apoptosis in hepatocytes. Primary rat hepatocytes, HepG2-rNtcp cells (human hepatocellular carcinoma cells) or H-
4-II-E cells (rat hepatoma cells) were exposed to glycochenodeoxycholic acid (GCDCA) or tumor necrosis factor-a (TNFa)/
actinomycin D (ActD). PT (50–200 nmol/L) was added 30 minutes prior to the apoptotic stimulus. Apoptosis (caspase-3
activity, acridine orange staining) and necrosis (sytox green staining) were assessed. PT significantly reduced GCDCA- and
TNFa/ActD-induced apoptosis in rat hepatocytes (260%, p,0.05) in a dose-dependent manner (with no shift to necrosis),
but not in HepG2-rNtcp cells or rat H-4-II-E cells. The protective effect of pertussis toxin was independent of the activation of
selected cell survival signal transduction pathways, including ERK, p38 MAPK, PI3K and PKC pathways, as specific protein
kinase inhibitors did not reverse the protective effects of pertussis toxin in GCDCA-exposed hepatocytes. Conclusion:
Pertussis toxin, an inhibitor of GaiPCRs, protects hepatocytes, but not hepatocellular carcinoma cells, against bile acid- and
cytokine-induced apoptosis and has therapeutic potential as primary hepatoprotective drug, as well as adjuvant in anti-
cancer therapy.
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Introduction
In chronic and acute liver diseases, the liver is exposed to
increased levels of cytokines, reactive oxygen species and bile
acids, all of which independently can lead to loss of functional liver
mass due to hepatocyte cell death. Concomitantly, hepatic stellate
cells become activated, start proliferating and produce excessive
amounts of extracellular matrix proteins leading to liver fibrosis,
which may progress to end-stage liver disease [1]. Hepatocyte cell
death can occur via apoptosis, necrosis or a combination of these
different types of cell death [2]. Apoptosis is an energy-dependent
process, resulting in the formation of apoptotic bodies. Apoptotic
bodies are cleared by surrounding phagocytizing cells that
minimize inflammation. In contrast, uncontrolled apoptosis and
(secondary) necrosis trigger inflammation in the liver [3,4]. Despite
worldwide efforts to establish therapeutic strategies for liver injury,
end-stage liver disease remains a high burden for public health due
to the lack of effective treatments. Excessive hepatocyte apoptosis
is often observed in liver disease and, as this is a highly controlled
cellular mechanism, drugs and therapeutic strategies to prevent
hepatocyte apoptosis may help to maintain sufficient liver mass
and function [1].
Recently, G-protein coupled receptors (GPCRs) have been
suggested as new drug targets to treat cardiac diseases and cancer,
as GPCRs play crucial roles in the regulation of cell proliferation,
angiogenesis, cell survival and apoptosis [5,6]. GPCRs are the
largest family of membrane proteins and are essential nodes of
communication between the internal and external environment of
the cells. Over 300 GPCRs have been reported in human and
rodents [7]. Upon activation by agonists, GPCRs activate
heterotrimeric G-proteins (Gabc). These subunits subsequently
activate second messengers (e.g. cAMP, Ca2+ and protein kinases),
submitting the GPCR induced-signal to the intracellular targets.
Heterotrimeric G-proteins are divided into 4 families (i.e., Gas,
Gai, Gaq/11 and Ga12/13) based on the Ga subunit sequence
identity and signaling activity [8].
A number of bacterial endotoxins are suggested as excellent
tools to study the function of GPCRs, as they covalently modify
the a-subunit of G-proteins, altering their function (reviewed in
[8]). Pertussis toxin (PT), an exotoxin produced by Bordetella
pertussis (the causative agent of whooping cough), is shown to be a
mono-ADP-ribosyltransferase that covalently modifies the a-
subunit of Gi proteins. This ribosylation is irreversible and
prevents the G-proteins from interacting with G protein-coupled
receptors on the cell membrane, thus interfering with intracellular
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communication [9–11]. As a result, the function of effector
proteins, such as adenylyl cyclase, ERK/MAPK and Ca2+
channels is changed and modulates cell proliferation, survival
and angiogenesis [8]. Interestingly, GPCRs antagonists have
shown excellent therapeutic benefits in clinical trials in controlling
tumor growth and apoptosis [6]. For example, an endothelin A
receptor antagonists ZD4054, has been shown to improve the
overall survival and reduce the risk of death and bone metastasis in
patients with resistant prostate cancer [12]. Therefore, GPCR-
based drugs may also show therapeutic benefits in regulation of
apoptosis and/or survival in liver diseases.
GPCRs are present in hepatocytes and play an important role in
the regulation of several hepatocyte functions, including gluco-
neogenesis and lipid storage [13–16]. In addition, lysophosphati-
dylcholine has been shown to act via a GaiPCR-dependent
mechanism in lipoapoptosis of hepatocytes [15]. Whether PT-
sensitive GPCRs also play a role in other apoptotic signals, like bile
acid- or cytokine-induced apoptosis, is not known. Liver injury
may be caused by (a combination of) inflammation, oxidative
stress and increased bile acid levels, leading to hepatocyte cell
death. Therefore in this study, we have investigated the effect of
PT-mediated inhibition of GPCRs in models of TNFa- and
GCDCA-induced apoptosis in primary rat hepatocytes. Our data
provide new information about the function of PT-sensitive




Specified pathogen-free male Wistar rats (220–250 g) were
purchased from Charles River Laboratories Inc. (Wilmington,
MA, USA). Animals were kept under standard laboratory
conditions with free access to standard laboratory chow and
water. The local Committee for Care and Use of laboratory
animals in University of Groningen specifically approved the
experiments of this study and all the experiments were performed
in accordance with the guidelines of this Committee.
Rat hepatocyte isolation
Hepatocytes were isolated by a two-step perfusion method using
collagenase as described before [17]. In brief, the liver was first
perfused through portal vein with Ca2+- free Krebs Ringer Hepes
buffer, pH 7.4, maintained at 37uC (10 min, flow rate = 25 ml/
min), followed by perfusion with Mg2+-free Krebs Ringer Hepes
buffer containing Ca2+ (5.7 mmol/L) and Collagenase type I
(Sigma-Aldrich; 0.12–0.16 U/ml, 10 min, flow rate 8 ml/min).
The liver was then removed and placed in the same buffer
containing 1% bovine serum albumin (BSA; Sigma-Aldrich) with-
out Collagenase. Hepatocytes were then released by gentle teasing
of the softened liver and filtered through 60-mesh sterile nylon
gauze. The dissected inferior vena cava was used as the outflow
port. The buffers were oxygenated prior to perfusion.
Cells were washed three times with HBSS at 50 g for 5 min and
the supernatant was discarded. The final cell pellet was re-
suspended and cultured in William’s E medium in a humidified
incubator at 37uC and 5% CO2 as described before [18].
Experimental design
Experiments were started after the attachment period of
4 hours. In order to inhibit the a-subunit of G-proteins,
monolayers of cultured primary hepatocytes were treated with
pertussis toxin (Calbiochem, VWR International, Amsterdam, the
Netherlands) at the indicated concentrations starting 30 minutes
prior to the exposure to 50 mmol/L GCDCA (Sigma-Aldrich) for
4 hours or 20 ng/ml recombinant murine TNFa (R&D Systems,
Abingdon, United Kingdom) for the indicated time period, unless
stated otherwise. Signal transduction pathways were inhibited
using 10 mmol/L of the ERK1/2 inhibitor U0126 ( Promega,
Madison, USA), 10 mmol/L of the p38 inhibitor SB 203580
(Calbiochem), 50 mmol/L of the PI3 kinase inhibitor LY 294002
(Calbiochem), 1 mmol/L of the protein kinase-C inhibitors
Calphostin-C and Bisindolylmaleimide I (BSM-I) (Calbiochem),
and 200 ng/ml of the transcriptional inhibitor actinomycin-D
(Roche Diagnostics, Almere, the Netherlands). All inhibitors and
receptor antagonists were added to the cultured hepatocytes
30 minutes prior to the apoptotic stimuli unless stated otherwise.
Each experimental condition was performed in triplicate. Each
experiment was repeated at least three times using hepatocytes
from different rats. Cells were harvested at the indicated time
points as described previously [18].
HepG2-rNtcp cell experiments
The human hepatoma cell line HepG2 stably expressing the bile
acid importer rNtcp was obtained from Dr. Bruno Stieger (Zurich,
Switzerland) [19]. The HepG2-rNTCP cells were cultured as
described before [20]. Cells were incubated with GCDCA
(200 mmol/L) or human recombinant TNFa (20 ng/ml) for the
indicated time points. The transcriptional inhibitor actinomycin-D
(Roche Diagnostics, Almere, the Netherlands) was added to the
cells prior to the addition of TNFa. Cells were treated with
pertussis toxin (200 nmol/L, Calbiochem, VWR International,
Amsterdam, the Netherlands) 30 minutes prior to the exposure to
GCDCA or TNFa/ActD. Cells were harvested at the indicated
time points in hypotonic cell lysis buffer [18].
Rat H-4-II-E hepatoma cell experiments
The rat hepatoma cell line H-4-II-E (European Collection of
Cell Culture, Salisbury, UK) was cultured in Earles modified
Eagles medium supplemented with 10% FCS, 2 mmol/L gluta-
mine, non-essential amino acids and penicillin/streptomycin/
fungizone as described before [21]. Cells were incubated with
GCDCA (50–500 mmol/L) or recombinant murine TNFa (20 ng/
ml) for the indicated time points. The transcriptional inhibitor
actinomycin-D (Roche Diagnostics, Almere, the Netherlands) was
added to the cells prior to the addition of TNFa. Cells were treated
with pertussis toxin (200 nmol/L, Calbiochem, VWR Interna-
tional, Amsterdam, the Netherlands) 30 minutes prior to the
exposure to GCDCA or TNFa/ActD. Cells were harvested at the
indicated time points in hypotonic cell lysis buffer [18].
Apoptosis and necrosis assays
Caspase-3 activity was measured as described previously [18].
The arbitrary fluorescence unit (AFU) was corrected for the
amount of protein. Protein concentration was determined using
the Bio-Rad protein assay kit. Sytox green (Invitrogen) and
acridine orange (Sigma-Aldrich) were used to visualize necrotic
and apoptotic cell death, respectively, as described before [22].
Statistical analysis
Results are presented as the mean of at least 3 independent
experiments 6 SD. A two-way ANOVA test was used to
determine the significance of differences between experimental
groups. A P-value of less than 0.05 (P,0.05) was considered
statistically significant.
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Figure 1. Pertussis toxin (PT) inhibits glycochenodeoxycholic acid (GCDCA)-induced caspase-3 activity and nuclear fragmentation.
(a) Primary rat hepatocytes were treated for 4 hours with 50 mmol/L of GCDCA, 200 nmol/L of PT or a combination of both. PT was added 30 min
prior to the addition of GCDCA. * P,0.05 for GCDCA + PT vs. GCDCA alone. (b) Hepatocytes were treated with different concentrations of PT 30 min
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Results
Pertussis toxin inhibits bile acid-induced caspase-3
activity and apoptotic nuclear morphology
GCDCA (at 50 mM) induces caspase-3 activity in primary rat
hepatocytes that peaks after 4 hours exposure [18]. The effect of
PT on GCDCA-induced caspase-3 activity in primary rat
hepatocytes was investigated at this time point. Exposure of
primary rat hepatocytes to PT (200 nmol/L) alone did not induce
caspase-3 activation in hepatocytes (Figure 1a), but significantly
inhibited GCDCA-induced caspase-3 activity in a dose-dependent
manner, with maximum inhibition observed at 200 nmol/L PT
(260%, P,0.05; Fig. 1a and 1b). In all subsequent experiments a
concentration of 200 nmol/L PT was used. PT attenuated the
GCDCA-induced caspase-3 activity at different apoptotic concen-
trations of GCDCA (50–200 mM; Fig. 1c). At higher GCDCA
concentrations, the primary mode of cell death shifts to necrosis
[22]. PT may delay, rather than prevent GCDCA-induced
apoptosis in rat hepatocytes. To establish whether PT prevents,
as opposed to delaying apoptosis, GCDCA-treated hepatocytes
were stained with acridine orange after 6 and 15 hours exposure
with and without PT. Nuclear fragmentation and condensation,
markers for end-stage apoptosis, were hardly detectable 6 hours
after the addition of GCDCA, but clearly increased over time
(shown for 15 hours exposure; Fig. 1d). The formation of
fragmented and condensed nuclei was inhibited when GCDCA-
exposed hepatocytes (both after 6 and 15 h) were co-treated with
PT, comparable to control levels (Fig. 1d). Importantly, PT alone
did not induce necrosis in hepatocytes, nor did it increase the
number of necrotic cells after exposure to GCDCA (Fig. 1e).
Time window of anti-apoptotic action of pertussis toxin
PT irreversibly inhibits Gai signaling. If Gai function is required
for bile acid-induced apoptosis, pre-incubation with PT alone
should also lead to inhibition of GCDCA-induced apoptosis in
hepatocytes. Hepatocytes were pre-incubated with PT for
15 hours, which results in complete ADP-ribosylation of Gai
proteins [23]. Medium was removed and cells were washed and
then exposed to GCDCA in fresh medium with or without PT for
4 hours. Caspase-3 activity was inhibited in the presence of PT
and the protective effect of PT persisted in hepatocytes exposed to
GCDCA in fresh medium without PT (Fig. 2a). These data show
that the anti-apoptotic effect of PT is sustained in hepatocytes,
suggesting that the protective effect of PT is mediated via PT-
catalyzed irreversible ribosylation of the a-subunit preventing the
G-proteins from interacting with GPCRs [11,24]. Furthermore,
addition of PT up to one hour after the start of the GCDCA
treatment still exerted maximum protection against GCDCA-
induced apoptosis (Fig. 2b). No protective effect of PT was
detected when PT was added at later time points (2–3 h after
GCDCA treatment; Fig. 2b). These data indicate that the anti-
apoptotic effect of PT is rapidly induced in hepatocytes and
suggest the involvement of Gai protein signaling pathways in the
protective action of PT against GCDCA-induced apoptosis [23].
Anti-apoptotic effect of pertussis toxin is not dependent
on the activation of ERK1/2, p38 MAP Kinase, PI3-kinase
and protein kinase C
To investigate whether specific protein kinase pathways are
involved in the anti-apoptotic effects of PT, GCDCA-exposed rat
hepatocytes were co-treated with inhibitors of MAPK, PI3K and
PKC. These inhibitors alone do not induce caspase-3 activity in
rat hepatocytes (data not shown) [18]. The protective effect of PT
against GCDCA-induced apoptosis was not abolished by inhibi-
tion of ERK1/2, p38 MAP kinases, PI3 kinase and PKC pathways
(Fig 3.). These inhibitors at the concentration tested here were
effective in our positive control experiments (Data S1 and [18]).
This suggests that the anti-apoptotic effect of PT is independent of
prior to the addition of 50 mmol/L of GCDCA for 4 hours. (c) PT (200 nmol/L) significantly inhibits GCDCA-induced caspase-3 activation. P,0.05 for
GCDCA (50, 100, 200 mM) + PT vs GCDCA (50, 100, 200 mM) alone. (d) Acridine orange staining. Treatment with 50 mmol/L of GCDCA induces nuclear
condensation and fragmentation (white arrows) which is blocked with 200 nmol/L PT at 15 hours after the addition of GCDCA. (e) Sytox green
staining. PT does not induce necrosis in hepatocytes after 15 hours. Hepatocytes treated with 5 mmol/L H2 O2 were used as positive control.
doi:10.1371/journal.pone.0043156.g001
Figure 2. The protective effect of pertussis toxin (PT) against glycochenodeoxycholic acid (GCDCA)-induced apoptosis. (a)
Hepatocytes were pre-incubated with 200 nmol/L of PT for 15 hours after which cells were washed and exposed to 50 mmol/L of GCDCA alone (+/2
PT) or with simultaneous addition of PT (+/+ PT). * P,0.05 for GCDCA + PT (+/2) and GCDCA + PT (+/+) vs. GCDCA 50 mM. (b) hepatocytes were
stimulated with 50 mmol/L GCDCA for 4 hours (GCDCA 50 mM). PT (200 nmol/L) was added 30 minutes prior to (230 min), simultaneous with (0 min)
or 30 minutes (+30 min), 1 hour (+1 hr), 2 hours (+2 hrs), 3 hours (+3 hrs) after the addition of GCDCA.* P,0.05 for 230 min of PT, 0 min of PT,
+30 min of PT, +1 hr of PT vs GCDCA alone.
doi:10.1371/journal.pone.0043156.g002
Pertussis Toxin Inhibits Apoptosis in Hepatocytes
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43156
the activation of these cell survival signaling kinases or that parallel
pathways contribute to the protective effect and that inhibition of
only one pathway does not result in increased apoptotic cell death.
Pertussis toxin protects hepatocytes against cytokine-
induced caspase-3 activation and apoptotic nuclear
morphology
We also analyzed the effect of PT on cytokine-induced apoptosis
in hepatocytes. TNFa, in combination with ActD, induces
caspase-3 activation in hepatocytes that peaks around 16 hours
[25]. PT significantly reduced TNFa/ActD-induced caspase-3
activity in rat hepatocytes (260%, P,0.05; Fig. 4a). Acridine
orange staining confirmed that TNFa/ActD-induced activation of
caspase-3 resulted in the formation of fragmented and condensed
nuclei, markers of end-stage apoptosis, after 16 hours (Fig. 4b).
Importantly, theses markers were absent when TNFa/ActD-
exposed hepatocytes were co-treated with PT, confirming that
apoptosis was strongly inhibited in the presence of PT (Fig. 4b).
Our data show that the PT-sensitive a-subunit of G-proteins is also
a key player in TNFa-induced apoptotic signal transduction in
primary rat hepatocytes.
Pertussis toxin does not inhibit apoptosis in HepG2-rNtcp
cells and rat H-4-II-E cells
To investigate whether PT has the same anti-apoptotic effect in
a human hepatocellular carcinoma cell line and a rat hepatoma
cell line as it has in primary rat hepatocytes, we investigated the
effect of PT in HepG2-rNtcp cells and rat H-4-II-E cells
respectively. HepG2-rNtcp cells and H4-II-E cells were pre-
treated with PT for 30 minutes, followed by exposure to GCDCA
for 4 hours or TNFa/ActD for 16 hours. PT did not induce
caspase-3 activity in HepG2-rNtcp nor did it inhibit GCDCA-
induced caspase-3 activation in these cells (Fig. 5a). Similarly, PT
did not reduce the TNFa/ActD-induced caspase-3 activity in
HepG2-rNtcp cells (Fig. 5b). Although GCDCA and TNFa/ActD
did not induce very high levels of active caspase-3 in H-4-II-E
(Fig. 5c and Fig. 5d), PT did not increase caspase-3 activity in H-4-
II-E cells nor did it inhibit GCDCA-induced caspase-3 activation
in these cells (Fig. 5c). Similarly, PT did not reduce the TNFa/
ActD-induced caspase-3 activity in H-4-II-E cells (Fig. 5d). These
data suggest that the PT-sensitive Ga-protein is specifically
involved in the apoptotic signaling pathways in primary hepato-
cytes and not in hepatocellular carcinoma cells.
Discussion
In this study, we report that PT, an inhibitor of Ga-proteins,
protects primary rat hepatocytes against bile acid- and cytokine-
induced apoptosis. These effects are specific for primary rat
hepatocytes and are not observed in the human hepatocellular
carcinoma cell line HepG2-rNtcp or rat hepatoma cell line H-4-II-
E cells. We demonstrate that the protective effect of PT is rapidly
induced in hepatocytes and is sustained in rat hepatocytes,
although the protective action of PT appears to be independent
of a single protein kinase (-signaling pathway). We propose that the
PT-sensitive a-subunit of G-proteins is a key player in apoptotic
signal transduction in rat hepatocytes.
Among the PT-sensitive G-proteins, the Gi family is the largest
family with wide expression in the different cells and Gbc signaling
is usually associated with the Gi family [8,26]. Other PT-sensitive
Figure 3. The protective effect of pertussis toxin (PT) is
independent of the activation of specific kinases. (a) Caspase-3
activity in rat hepatocytes treated with 50 mmol/L of GCDCA in the
presence and absence of 200 nmol/L PT and with or without the
inhibitors of ERK1/2- MAPK (10 mmol/L of U0126; U0), p38 MAPK
(10 mmol/L of SB 203580; SB), PI3K (50 mmol/L of LY 294002; LY), PKC
inhibitors (1 mmol/L of calphostin-C, 1 mmol/L of BSM-I).
doi:10.1371/journal.pone.0043156.g003
Figure 4. Pertussis toxin (PT) inhibits tumor necrosis factor-a/actinomycin-D (TNFa/ActD)-induced caspase-3 activity and nuclear
fragmentation. (a) Primary rat hepatocytes were treated for 16 hours with 20 ng/ml of TNFa in the presence of 200 ng/ml of ActD. 200 nmol/L of
PT was added 30 min prior to the addition of TNFa/ActD. * P,0.05 for TNFa/ActD + PT vs. TNFa/ActD alone. (b) Acridine orange staining. Treatment
with TNFa/ActD induces nuclear condensation and fragmentation which is blocked with 200 nmol/L PT.
doi:10.1371/journal.pone.0043156.g004
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G-proteins have a more restricted distribution in neuroendocrine,
visual and lingual tissues [8]. Regulation of gluconeogenesis by bile
acids and regulation of lipoapoptosis by lysophosphatidylcholine
has previously been shown to be mediated via GaiPCR-dependent
mechanisms in hepatocytes [13,15]. Our data suggest that PT-
sensitive GPCRs (likely GaiPCRs) are involved in bile acid- and
cytokine-induced apoptotic signal transduction in primary rat
hepatocytes as well.
The specific effect of PT (i.e. catalyzing ribosylation) on the a-
subunit of Gi-proteins can explain the rapidly induced and
sustained (protective) effect of PT in our experiments. ADP-
ribosylated Gai-proteins are in an ‘‘off’’ state and cannot transduce
GPCR-induced signals [11,27]. Therefore the receptors that are
coupled to these G-proteins are not able to induce signaling
pathways upon activation by agonists.
MAP kinase-, PI3 kinase- and PKC-signaling pathways play
important roles in regulating hepatocyte death and survival in
response to stress inducers [28–31]. In addition, the cross-talk
between GPCRs and these signaling pathways is responsible for
cellular responses, such as cell proliferation, survival, migration
and differentiation [32]. Interestingly, our findings indicate that
the protective effect of the pertussis toxin against GCDCA-
induced apoptosis is not grossly dependent on one of these
signaling pathways and may actually be completely independent of
these signaling cascades. This finding is remarkable because it has
been reported that conjugated bile acids such as GCDCA induce
phosphorylation of ERK1/2 and PI3K/Akt pathways in a PT-
sensitive manner in primary rat hepatocytes [14]. Thus, one may
assume that co-treatment with PT hypersensitizes hepatocytes to
GCDCA-induced apoptosis via inhibiting cell survival pathways
(e.g., ERK and PI3K/Akt). However, our findings demonstrate
the opposite. It is accepted that PT is a general inhibitor for Gai-
proteins and inhibits several GaiPCRs signal transduction path-
ways [8]. Therefore, it is likely that despite the inhibitory effect of
PT on GCDCA-induced ERK1/2 and PI3K/Akt phosphoryla-
tion, the overall effect of PT in GCDCA-treated hepatocytes
favors cell survival.
TNFa/ActD induces apoptosis in hepatocytes via the activation
of death receptor signaling cascade (extrinsic pathway), whereas
GCDCA induces apoptosis in hepatocytes via the activation of the
mitochondria-dependent apoptotic cascade (intrinsic pathway)
[25,33]. However, there is cross-talk between the bile acid-induced
and cytokine-induced signaling cascades in hepatocytes [34,35].
Ligand-independent transactivation of tyrosine kinase receptors,
such as EGFR, is one of the crucial steps in the cross-talk between
the intrinsic and the extrinsic apoptotic pathways in rat
hepatocytes [35]. Tyrosine kinase receptor transactivation has
been associated with GPCRs (reviewed in [36]). Given the
involvement of EGFR transactivation in rat hepatocyte apoptosis
(Data S2 and [35]) and the anti-apoptotic effect of PT in rat
hepatocytes (our data), we suggest that there is cross-talk between
PT-sensitive GPCR/Gai and the EGFR, which leads to apoptosis.
Indeed, it has been observed that PT pretreatment of hepatocytes
inhibited taurodeoxycholic acid (TDCA)-induced activation of the
Figure 5. Pertussis toxin (PT) does not inhibit apoptosis in HepG2-rNtcp cells and rat H-4-II-E cells. (a) Caspase-3 activity in HepG2-rNtcp
cells treated with 200 mmol/L of GCDCA in the presence and absence of 200 nmol/L PT. (b) HepG2-rNtcp cells were treated for 16 hours with 20 ng/
ml of TNFa in the presence of 200 ng/ml of ActD. 200 nmol/L of PT was added 30 min prior to the addition of TNFa/ActD. (c) Caspase-3 activity in rat
H-4-II-E cells treated with 50–500 mmol/L of GCDCA in the presence and absence of 200 nmol/L PT. (d) Rat H-4-II-E cells were treated for 16 hours
with 20 ng/ml of TNFa in the presence of 200 ng/ml of ActD. 200 nmol/L of PT was added 30 min prior to the addition of TNFa/ActD.
doi:10.1371/journal.pone.0043156.g005
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EGFR [14]. It is also reported that PT-sensitive Gi proteins are
uniquely involved in the signal transduction pathway mediating
EGF-induced activation of phospholipase C-gamma (PLCc) and
Ca2+ mobilization (via tyrosine phosphorylation of EGFR) in rat
hepatocytes, but not in a rat liver cell line (WB) [37]. Whether
GCDCA-induced activation of EGFR in primary hepatocytes is
also PT-sensitive remains to be determined.
PT has no effect on apoptotic signaling pathways induced by
GCDCA and TNFa/ActD in HepG2-rNtcp cells and rat H-4II-E
hepatoma cells. This could be related to differences between
(transformed) hepatoma cell lines and primary hepatocytes with
regard to gene expression patterns, signaling cascades, GPCRs
expression patterns and/or the ability of Gai proteins to interact
with the effector receptors such as EGFR [38,39]. Indeed, it has
been shown that Gai proteins are unable to produce a stable
complex with the EGFR or other EGFR-induced signaling protein
kinases (such as PLCc) in the rat epithelial liver cell line, WB [37].
It is known that liver injury is often accompanied by apoptotic
hepatocyte cell death [1]. High levels of bile acids, cytokines,
reactive oxygen species, drugs and toxins can induce hepatocyte
apoptosis. In the liver, massive hepatocyte apoptosis results in
acute liver failure, whereas persistent hepatocyte apoptosis and
necrosis is often associated with activation of hepatic stellate cells
and fibrogenesis, chronic liver dysfunction and end-stage liver
disease [1,3]. Ideally, the most direct therapeutic strategy is to
eliminate the cause of the liver injury. However, effective
treatments do not exist for many liver diseases, including primary
sclerosing cholangitis, NASH, alcohol-mediated hepatitis, viral
hepatitis unresponsive to antiviral therapies and acute liver failure.
Anti-apoptotic interventions are among the most promising
therapeutic strategies for these diseases as they may reduce the
apoptosis induced-inflammation and fibrogenesis [1,40,41].
GPCRs, are suggested as novel targets for drug innovation, as
they have pivotal roles in many physiologic functions (e.g., cell
proliferation, angiogenesis, survival) and in multiple diseases
including the development of cancer and cancer metastasis.
Excellent therapeutic benefits have been observed with some
GPCR-based drugs in clinical trials: e.g., the endothelin A
receptor antagonists ZD4054 and atrasentan show good antitumor
efficacy for ovarian and prostate cancer [5,6,42,43]. GPCRs (e.g.,
orexin receptor, GPCR78 and LPA receptor) are also involved in
the regulation of apoptosis in cancer cells via interaction with
different intracellular regulators of apoptosis such as MAPK-, NF-
kB- and p53-associated pathways (reviewed in [6]). The partici-
pation of GPCR/Gai in hepatocyte apoptosis suggests new targets
for drug innovation for (chronic) liver diseases and liver cancer
treatment in the future. E.g., activating death receptor-mediated
apoptosis in cancer cells by death ligands (such as TRAIL, FasL
and TNFa) is suggested as an effective therapeutic strategy in the
treatment of hepatocellular carcinoma [44]; however, this strategy
may lead to the induction of apoptosis in adjacent normal
hepatocytes and loss of functional tissue. In this situation, an
adjuvant anti-apoptotic therapy that will inhibit cell death in
normal hepatocytes but has no effect on cancer cells may prevent
excessive liver damage. Our data suggest that GPCR/Gai-based
therapeutic strategies may serve as the anti-apoptotic adjuvant
therapy, protecting normal tissue against inflammation, bile acid
and/or drug-induced cell death.
In summary, our data indicate that GPCRs/Gai participates in
several apoptotic signaling pathways in hepatocytes, but not in
human hepatocellular carcinoma cells, and that inhibiting the ai
subunit of G-proteins is a very effective anti-apoptotic strategy in
vitro. The participation of GPCR/Gai in hepatocyte apoptosis
unveils new targets for drug innovation to treat liver diseases in the
future.
Supporting Information
Data S1 U0126 (ERK1/2 inhibitor), Calphostin-C and
Bisindolylmaleimide I (BSM-I), protein kinase-C inhib-
itors inhibit ERK and PKC phosphorylation in rat
hepatocytes, respectively. (a) Primary rat hepatocytes were
treated for 15 min with 20 ng/ml of TNFa in the presence and
absence of the inhibitor of ERK1/2- MAPK (10 mmol/L of
U0126; U0). Westernblotting was perfomed on cell lysates.
Expression of selected protein was assessed using monoclonal
mouse antibody against phosphorylated ERK1/2 (p44/42) at a
dilution of 1:1000. Blots were subsequently stripped using 0.1%
SDS/0.1% Tween – PBS at 65uC for 30 minutes and incubated
with 1:4000 diluted monoclonal mouse antibody against GAPDH
(Calbiochem, La Jolla, CA. USA). Horse radish-peroxidase
conjugated rabbit anti-mouse Ig (DAKO, Denmark) was used
every time as a secondary antibody at a dilution of 1:2000. (b)
Primary rat hepatocytes were treated for 15 min with 50 mmol/L
of GCDCA in the presence and absence of the inhibitor of PKC
inhibitors (1 mmol/L of calphostin-C, 1 mmol/L of BSM-I).
Westernblotting was perfomed on cell lysates. Expression of
selected protein was assessed using polyclonal rabbit antibody
against phosphorylated PKC (abcam, Cambridge, MA) at a
dilution of 1:500. Blots were subsequently stripped using 0.1%
SDS/0.1% Tween – PBS at 65uC for 30 minutes and incubated
with 1:4000 diluted monoclonal mouse antibody against GAPDH
(Calbiochem, La Jolla, CA. USA). Horse radish-peroxidase
conjugated rabbit anti-mouse Ig (DAKO, Denmark) was used
every time as a secondary antibody at a dilution of 1:2000.
(TIF)
Data S2 EGFR inhibitor (AG1478) inhibits glycocheno-
deoxycholic acid (GCDCA)-induced caspase-3 activity in
rat hepatocytes. Primary rat hepatocytes were treated for
4 hours with 50 mmol/L of GCDCA, in the absence or presence
of 200 nmol/L of PT and with or without the EGFR inhibitor
(25 mmol/L, AG1478). PT and AG1478 were added 30 min prior
to the addition of GCDCA. * P,0.05 for GCDCA + PT, GCDCA
+ AG1478 and GCDCA + PT + AG 1478 vs. GCDCA and alone.
(TIF)
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